BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 15182336)

  • 1. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
    Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
    Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Leuk Lymphoma; 2006 Jun; 47(6):1034-40. PubMed ID: 16840194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
    Gora-Tybor J; Blonski JZ; Robak T
    Mediators Inflamm; 2003 Jun; 12(3):167-71. PubMed ID: 12857600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.
    Lai R; O'Brien S; Maushouri T; Rogers A; Kantarjian H; Keating M; Albitar M
    Cancer; 2002 Sep; 95(5):1071-5. PubMed ID: 12209693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenin expression and prognosis in primary breast carcinoma.
    Montero S; Guzmán C; Cortés-Funes H; Colomer R
    Clin Cancer Res; 1998 Sep; 4(9):2161-8. PubMed ID: 9748135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
    Molica S; Digiesi G; Mirabelli R; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Morabito F; Neri A; Baldini L; Ferrarini M
    Eur J Haematol; 2009 Sep; 83(3):208-14. PubMed ID: 19459926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma.
    Fang S; Repo H; Joensuu H; Orpana A; Salven P
    Eur J Cancer; 2011 Jul; 47(11):1708-16. PubMed ID: 21439815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
    Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
    Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
    Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
    Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
    Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.